Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


«12...4647484950515253545556...401402»
  • ||||||||||  IS SARCOPENIA A REAL PROBLEM IN PATIENTS WITH ANKYLOSING SPONDYLITIS? A SYSTEMATIC LITERATURE REVIEW () -  May 29, 2024 - Abstract #EULAR2024EULAR_2893;    
    While the exact mechanisms contributing to muscle damage remain a subject of debate, factors such as inflammation, diminished physical activity, a sedentary lifestyle, glucocorticoid therapy, and neuromuscular impairment may play significant roles (refer to Figure 1 ). Effectively managing AS patients necessitates a multidisciplinary non-pharmacological approach, emphasizing the early implementation of physical therapy and rehabilitation programs, as bDMARDs alone prove insufficient for the restoration of optimal muscle health.
  • ||||||||||  ASSESSING THE IMPACT OF SARCOPENIA IN AXIAL SPONDYLOARTHRITIS () -  May 29, 2024 - Abstract #EULAR2024EULAR_2848;    
    In practice, SARC-F is a valuable screening tool for the evaluation of sarcopenia in patients with AxSpA. Considering sarcopenia in the overall management of AxSpA might help improve clinical care of patients.
  • ||||||||||  Review, Journal:  Effects of Multidomain Interventions on Sarcopenia. (Pubmed Central) -  May 29, 2024   
    While the updated literature highlights the beneficial consequences of multidomain interventions in enhancing physical performance outcomes, gaps persist in understanding their influence on the biological aspects of sarcopenia. Promising initial findings suggest changes in plasma inflammatory markers or muscle turnover networks, but further research is necessary to clarify the disease-modifying effects of multidomain intervention in sarcopenic patients.
  • ||||||||||  Trial completion:  Auto-regulated Resistance-training for Older Adults (clinicaltrials.gov) -  May 29, 2024   
    P=N/A,  N=36, Completed, 
    Unknown status --> Recruiting | N=50 --> 100 | Trial completion date: Dec 2021 --> Nov 2024 | Trial primary completion date: Nov 2021 --> Nov 2024 Recruiting --> Completed
  • ||||||||||  Journal:  Expert consensus report on lipid mediators: Role in resolution of inflammation and muscle preservation. (Pubmed Central) -  May 28, 2024   
    This consensus not only reaffirms the role of specific lipid components in enhancing patient outcomes, but also suggests a shift towards nutrition-based therapeutic strategies in clinical settings, advocating for the proactive evidence-based use of lipid emulsions enriched with omega-3 PUFAs. Furthermore, we should seek to apply our knowledge concerning DHA, EPA, and their SPM derivatives, to produce more informative randomized controlled trial protocols, thus allowing more authoritative clinical recommendations.
  • ||||||||||  Journal:  Editorial: Body composition and cardiovascular health. (Pubmed Central) -  May 28, 2024   
    Our results showed that a reverse U-shaped curve between blood Mn levels and sarcopenia, with an identified the inflection point at blood Mn level of 13.45??g/L. No abstract available
  • ||||||||||  sirolimus / Generic mfg.
    Review, Journal:  Dietary protein and amino acid intakes for mitigating sarcopenia in humans. (Pubmed Central) -  May 28, 2024   
    Acute, short-term, or long-term administration of some of these AAs or a mixture of proteinogenic AAs can enhance blood flow to skeletal muscle, activate the mechanistic target of rapamycin cell signaling pathway for the initiation of muscle protein synthesis, and modulate the metabolic activity of the muscle...Long-term adequate intakes of protein and the AA metabolites can aid in mitigating sarcopenia in elderly adults. Appropriate combinations of animal- and plant-sourced foods are most desirable to maintain proper dietary AA balance.
  • ||||||||||  Review, Journal:  New advances of adiponectin in regulating obesity and related metabolic syndromes. (Pubmed Central) -  May 27, 2024   
    The modulation of ADP genes, multimerization, and secretion covers the main processes of ADP generation, providing a comprehensive orientation for the development of more appropriate therapeutic strategies. In order to have a deeper understanding of ADP, this paper will provide an all-encompassing review of ADP.
  • ||||||||||  Review, Journal:  The nutritional support to prevent sarcopenia in the elderly. (Pubmed Central) -  May 27, 2024   
    In addition, of relevant importance appears to be the supplementation with vitamin D, with omega-3 fatty acids and probiotics. This review evaluates the results of the most qualified studies on the nutritional supplementation of sarcopenic elderly subjects and shows that promising results have been achieved in community elderly subjects, or subjects followed in rehabilitation centers and in nursing homes, with additional resistance exercise programs.
  • ||||||||||  Journal:  Muscle strength in ostensibly healthy non-diabetic subjects. (Pubmed Central) -  May 26, 2024   
    These data will be useful as normal controls for muscle strength of specific disease groups. The application of the cutoffs from these data and their comparisons with the recommended cutoffs from various guidelines worth further exploration.
  • ||||||||||  Journal:  Sarcopenia: a dive into metabolism to promote a multimodal, preventive, and regenerative approach. (Pubmed Central) -  May 26, 2024   
    By synthesizing current research findings and theoretical frameworks, this perspective elucidates the multifaceted mechanisms underlying sarcopenia, mainly focusing on energy balance and metabolic processes. Furthermore, the manuscript explores the implications of sarcopenia on overall health outcomes, functional decline, and quality of life in older individuals.
  • ||||||||||  Journal:  SuperAgers and Centenarians, Dynamics of Healthy Ageing with Cognitive Resilience. (Pubmed Central) -  May 26, 2024   
    Our article aims to examine the factors associated with healthy ageing, particularly focusing on cognitive health in centenarians. We will also be discussing different aspects of ageing including genomic instability, metabolic burden, oxidative stress and inflammation, mitochondrial dysfunction, cellular senescence, immunosenescence, and sarcopenia.
  • ||||||||||  Retrospective data, Journal, Surgery:  Sarcopenia, a Risk Predictor of Postoperative Acute Kidney Injury in Elderly Patients after Hip Fracture Surgery: A Retrospective Analysis. (Pubmed Central) -  May 25, 2024   
    According to the multivariate logistic regression, which included all variables with a p value < 0.05 in the univariate analysis and adjusted for age, body mass index (BMI) and American Society of Anesthesiologists (ASA) physical status, sarcopenia was revealed to be an independent predictor of postoperative AKI (odds ratio = 5.10, 95% confidence interval = 1.77-14.77; p = 0.003). Preoperative sarcopenia, which corresponds to the lowest quartile of PLVI values, is associated with postoperative AKI among elderly patients who underwent hip fracture surgery.
  • ||||||||||  Observational data, Journal:  Sarcopenia Prevalence among Hospitalized Patients with Severe Obesity: An Observational Study. (Pubmed Central) -  May 25, 2024   
    The application of ESPEN/EASO-SO criteria in a cohort of inpatients with severe obesity revealed 11.48% SO prevalence, which was associated with age (particularly > 70 years), gender (women), but not BMI, as determinants. Disease staging and QoL screening may improve the identification of SO high-risk patients.
  • ||||||||||  Review, Journal, Surgery:  Multi-Modal Prehabilitation in Thoracic Surgery: From Basic Concepts to Practical Modalities. (Pubmed Central) -  May 25, 2024   
    All patients may benefit from prehabilitation, which is part of the enhanced recovery after surgery (ERAS) programs. Faster functional recovery is expected in low-risk patients, whereas better clinical outcome and shorter hospital stay have been demonstrated in higher risk and physically unfit patients.
  • ||||||||||  Review, Journal:  Skeletal Muscle Injury in Chronic Kidney Disease-From Histologic Changes to Molecular Mechanisms and to Novel Therapies. (Pubmed Central) -  May 25, 2024   
    To identify causes, affected cell types, and the mechanisms of sarcopenia and thereby novel targets for therapeutic interventions, it is important to first characterize the precise pathologic changes on molecular, cellular, and histologic levels, and to do so in CKD patients as well as in animal models of CKD, which we describe here in detail. We also discuss the currently known pathomechanisms and therapeutic approaches of CKD-associated sarcopenia, as well as the effects of hyperphosphatemia and the novel drug targets it could provide to protect skeletal muscle in CKD.
  • ||||||||||  Review, Journal:  Physical Activity and Oxidative Stress in Aging. (Pubmed Central) -  May 25, 2024   
    In this review, we analyzed what is reported by several authors regarding the role of physical activity on oxidative stress in the aging process as well as the role of hormesis and physical exercise as tools for the prevention and treatment of sarcopenia, an aging-related disease. Finally, we reported what has recently been studied in relation to the effect of physical activity and sport on aging in women.
  • ||||||||||  Clinical data, Journal:  Clinical outcomes of multidimensional association of type 2 diabetes mellitus, COVID-19 and sarcopenia: an algorithm and scoping systematic evaluation. (Pubmed Central) -  May 25, 2024   
    Thirty-three studies reported a relationship between sarcopenia with T2DM, twenty-one studies reported the prognosis COVID-19 in patients with T2DM, ten studies reported the prognosis of COVID-19 in patients with sarcopenia, five studies discussed the outcomes of sarcopenia in patients with COVID-19, and one study reported sarcopenia outcomes in the presence of T2DM and COVID-19. There is an obvious multidimensional relationship between T2DM, COVID-19 and sarcopenia which can cause prejudicial effects, poor prognosis, prolonged hospitalisation, lowered quality of life and a higher mortality rate during the current COVID-19 pandemic.
  • ||||||||||  Review, Journal:  Sarcopenia as a Risk Factor for Alzheimer's Disease: Genetic and Epigenetic Perspectives. (Pubmed Central) -  May 25, 2024   
    We also discuss the epigenetic regulation of each of these genes along with non-coding RNAs (ncRNAs) that may have a role in the development of both the sarcopenic and Alzheimer's disease phenotypes. Finally, we assert that the application of systems biology will unravel the relationship between sarcopenia and Alzheimer's disease and believe that the prevention of muscle loss in older age will reduce the incidence of debilitating cognitive decline.